The U.S. FDA has approved Merck’s Keytruda Qlex, a subcutaneous formulation of the blockbuster immunotherapy, enabling administration in about one minute compared to the 30-minute intravenous infusion of the original drug. This approval marks Keytruda’s first and only subcutaneous immune checkpoint inhibitor status, potentially improving patient convenience and healthcare efficiency. The injectable combines pembrolizumab with berahyaluronidase alfa-pmph to facilitate absorption. This development follows robust clinical data confirming comparable efficacy and safety to the intravenous version, reinforcing Merck’s leading position in oncology therapeutics.